NOVARTIND
NSENovartis India Limited (SMALL CAP)
Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹1,301.60
28.10 (2.11%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹3.21K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
N/A
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹950+37.0%
52W High₹1,589.2-18.1%
Current Price
₹1,301.60
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹1,041.28
Upper Circuit₹1,561.92
Reference Price
₹1,301.60
Investment Checklist
Trend: Price below most MAs — downtrend
EMA(20) Crossover: Price crossed below EMA(20): Fresh bearish weakness signal.
SuperTrend(10,3): Price above SuperTrend (Industry Standard (Swing/Medium-Term))
SuperTrend(7,3): Price above SuperTrend (Responsive Setting (Day Trading/Short-Term))
News: India needs to remain attractive for innovation-led investment: Judith Love, Nov...
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
74%
Trend
BEARISH
BEARISH
Price below most MAs — downtrend
EMA20
1318.82
Price Action
DOWNTREND
BEARISH
Higher Highs2
Higher Lows2
Lower Highs7
Lower Lows7
Support & Resistance Levels
Resistance (Above)
₹1589.20
Support (Below)
₹1273.55
₹1059.90
₹950.00
Volume Analysis
TrendDECREASING
Change-50.30%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹1288.58
3% Risk₹1262.55
5% Risk₹1236.52
7% Risk (Custom)
₹1210.49Technical Levels
1x ATR (Volatility)₹1227.27
2x ATR (Swing)₹1152.94
3x ATR (Trend)₹1078.61
Immediate Support₹1273.55
Financials
Financial data not available
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Latest News
News for NOVARTIND
View All
positive
ET Markets - Industry 1d ago
India needs to remain attractive for innovation-led investment: Judith Love, Novartis
With an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The company underscores the importance of collaboration to tackle obstacles like high costs and inadequate infrastructure.
BFINVESTNOVARTINDFinancial ServicesHealthcare
negative
ET Markets - Industry 12d ago
Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study
Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, even in patients who previously received Novartis' Pluvicto. Response rates were higher in patients without prior Pluvicto treatment. Larger trials are planned to assess side effects. Novartis is increasing its focus on radioligand therapies.
FOCUSNOVARTINDConsumer DurablesHealthcare
NEWS
positive
Business Standard - Markets 31d ago
Novartis India standalone net profit declines 13.82% in the March 2026 quarter
Sales rise 7.95% to Rs 90.55 crore
NOVARTINDHealthcare